169 related articles for article (PubMed ID: 17042691)
1. Differential evolution of thyroid peroxidase and thyrotropin receptor antibodies in Graves' disease: thyroid peroxidase antibody activity reverts to pretreatment level after carbimazole withdrawal.
Guilhem I; Massart C; Poirier JY; Maugendre D
Thyroid; 2006 Oct; 16(10):1041-5. PubMed ID: 17042691
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
Maugendre D; Massart C
Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
[TBL] [Abstract][Full Text] [Related]
3. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
Chen W; Man N; Li YS; Shan ZY; Teng WP
Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
[TBL] [Abstract][Full Text] [Related]
4. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
[TBL] [Abstract][Full Text] [Related]
5. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
[TBL] [Abstract][Full Text] [Related]
6. Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy.
Choi YM; Kwak MK; Hong SM; Hong EG
Endocrinol Metab (Seoul); 2019 Sep; 34(3):268-274. PubMed ID: 31565879
[TBL] [Abstract][Full Text] [Related]
7. Clinical validity of a new commercial method for detection of TSH-receptor binding antibodies in sera from patients with Graves' disease treated with antithyroid drugs.
Massart C; Orgiazzi J; Maugendre D
Clin Chim Acta; 2001 Feb; 304(1-2):39-47. PubMed ID: 11165197
[TBL] [Abstract][Full Text] [Related]
8. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
[TBL] [Abstract][Full Text] [Related]
9. Changes in thyroid-stimulating antibody activity in Graves' disease treated with antithyroid drug and its relationship to relapse: a prospective study.
Teng CS; Yeung RT
J Clin Endocrinol Metab; 1980 Jan; 50(1):144-7. PubMed ID: 6892512
[TBL] [Abstract][Full Text] [Related]
10. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment.
Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Bucci I; Carpentieri M; Di Nenno B; Di Blasio A; Vitti P; Monaco F; Napolitano G
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1080-7. PubMed ID: 22492869
[TBL] [Abstract][Full Text] [Related]
11. Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease.
Yamano Y; Takamatsu J; Sakane S; Hirai K; Kuma K; Ohsawa N
Thyroid; 1999 Aug; 9(8):769-73. PubMed ID: 10482368
[TBL] [Abstract][Full Text] [Related]
12. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease.
Nakazato N; Yoshida K; Mori K; Kiso Y; Sayama N; Tani JI; Nakagawa Y; Ito S
Thyroid; 1999 Aug; 9(8):775-9. PubMed ID: 10482369
[TBL] [Abstract][Full Text] [Related]
13. Relationship between CTLA-4 and CD28 molecule expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves' disease.
Bossowski A; Stasiak-Barmuta A; Urban M
Horm Res; 2005; 64(4):189-97. PubMed ID: 16220002
[TBL] [Abstract][Full Text] [Related]
14. The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of ophthalmopathy.
Khoo DH; Ho SC; Seah LL; Fong KS; Tai ES; Chee SP; Eng PH; Aw SE; Fok AC
Thyroid; 1999 Dec; 9(12):1175-80. PubMed ID: 10646655
[TBL] [Abstract][Full Text] [Related]
15. Outcome of treatment of hyperthyroidism.
Bringmann IM; van Leeuwen BL; Hennemann G; Beckett GJ; Toft AD
J Endocrinol Invest; 1999 Apr; 22(4):250-6. PubMed ID: 10342357
[TBL] [Abstract][Full Text] [Related]
16. Thyroid autoantibody profiles in ophthalmic dominant and thyroid dominant Graves' disease differ and suggest ophthalmopathy is a multiantigenic disease.
Goh SY; Ho SC; Seah LL; Fong KS; Khoo DH
Clin Endocrinol (Oxf); 2004 May; 60(5):600-7. PubMed ID: 15104563
[TBL] [Abstract][Full Text] [Related]
17. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
[TBL] [Abstract][Full Text] [Related]
18. The effect of thyrotropin-receptor blocking antibodies on stimulating autoantibodies from patients with Graves' disease.
Lenzner C; Morgenthaler NG
Thyroid; 2003 Dec; 13(12):1153-61. PubMed ID: 14751037
[TBL] [Abstract][Full Text] [Related]
19. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
Wallaschofski H; Miehle K; Mayer A; Tuschy U; Hentschel B; Paschke R
Horm Metab Res; 2002 Jul; 34(7):383-8. PubMed ID: 12189586
[TBL] [Abstract][Full Text] [Related]
20. Clinical validity of intercellular adhesion molecule-1 (ICAM-1) and TSH receptor antibodies in sera from patients with Graves' disease.
Massart C; Sonnet E; Gibassier J; Maugendre D; Genetet B
Clin Chim Acta; 1997 Sep; 265(2):157-68. PubMed ID: 9385458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
